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Alcoholic liver disease (ALD) is a leading cause of cirrhosis, 
liver cancer, and acute and chronic liver failure and as such 
causes significant morbidity and mortality. While alcohol 
consumption is slightly decreasing in several European coun-
tries, it is rising in others and remains high in many coun-
tries around the world. The pathophysiology of ALD is still 
incompletely understood but relates largely to the direct toxic 
effects of alcohol and its main intermediate, acetaldehyde. 
Recently, novel putative mechanisms have been identified 
in systematic scans covering the entire human genome and 
raise new hypotheses on previously unknown pathways. The 
latter also identify host genetic risk factors for significant liver 
injury, which may help design prognostic risk scores. The 
diagnosis of ALD is relatively easy with a panel of well-evalu-
ated tests and only rarely requires a liver biopsy. Treatment 
of ALD is difficult and grounded in abstinence as the pivotal 
therapeutic goal; once cirrhosis is established, treatment 
largely resembles that of other etiologies of advanced liver 
damage. Liver transplantation is a sound option for carefully 
selected patients with cirrhosis and alcoholic hepatitis be-
cause relapse rates are low and prognosis is comparable to 
other etiologies. Still, many countries are restrictive in allocat-
ing donor livers for ALD patients. Overall, few therapeutic op-
tions exist for severe ALD. However, there is good evidence of 
benefit for only corticosteroids in severe alcoholic hepatitis, 
while most other efforts are of limited efficacy. Considering 
the immense burden of ALD worldwide, efforts of medical 
professionals and industry partners to develop targeted 
therapies in ALF has been disappointingly low. (Gut Liver 
2017;11:173-188)
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INTRODUCTION
Alcohol consumption accounts for approximately 3.8% of all 
global deaths and 4.6% of global disability-adjusted life-years.1 
In Europe, this problem seems to be particularly relevant, with 
6.5% of all deaths attributable to alcohol,2 and recent estimates 
indicate that harmful drinking, particularly when associated 
with alcohol dependence, is responsible for one in seven deaths 
in men and one in 13 deaths in women aged 15 to 64 years.3 
Alcohol use disorders (AUD) are the most frequent cause of liver 
cirrhosis in Europe, and alcoholic liver disease (ALD) the most 
important cause of death due to alcohol in adults.4 Liver cir-
rhosis mortality over the past 30 years declined in most Western 
European countries, while it increased in several Eastern Euro-
pean countries, as well as in the United Kingdom, Ireland, and 
Finland.5 Of note, the all-cause mortality of middle-aged white 
non-Hispanic men and women in the United States between 
1999 and 2013 increased significantly, largely to increasing 
death rates from drug and alcohol poisonings, chronic liver 
diseases and cirrhosis.6 A strong determinant for alcohol-related 
organ damage in many–but not all–patients is the alcohol 
dependence syndrome, a common behavioral disorder charac-
terized by tolerance to the psychotropic effects of alcohol con-
sumption, a preoccupation with alcohol and persistent drinking 
despite its harmful consequences. Chronic and episodes of binge 
alcohol abuse also contribute to the development of various 
somatic and psychiatric disorders and injuries, as well as to sev-
eral diseases which are predominantly or entirely attributable 
to alcohol, such as alcohol-induced pancreatitis7 and the fetal 
alcohol syndrome.8 Furthermore, alcohol is also a contributory 
factor to other, diseases and injuries. Among the most impor-
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tant disease conditions affected by alcohol consumption are 
cancers of the oropharynx, esophagus, liver, colon, rectum and 
the female breast;9 cardiovascular diseases;10 neuropsychiatric 
disorders (epilepsy, depressive disorders);11 a (not necessarily 
complete) summary of physical and mental diseases related to 
alcohol consumption is given in Table 1. 
EPIDEMIOLOGY AND BURDEN OF DISEASE
AUD contributes to a large proportion of deaths from liver 
diseases, either by causing genuine ALD or as a cofactor in pa-
tients with non-ALDs such as chronic viral hepatitis, hemochro-
matosis and fatty liver due to nonalcoholic causes. The Global 
Burden of Disease Study reported a steadily increasing mortality 
due to liver diseases with approximately 1 million deaths in 
2010, which is roughly 2% of the global total mortality.12 With 
this, liver-related years of liver lost (YYL) outscore that of YYL 
due to cancers of the respiratory tract, esophagus, stomach, 
colorectum and pancreas together.13 To what proportion alcohol 
consumption contributes to this burden, is not entirely clear 
since the underlying etiologies of liver disease are not gaplessly 
recorded in most countries, with great variation across Europe. 
The most precise figures can be obtained from Finland where 
87% of death cases due to liver disease seem to be alcohol-relat-
ed. Taking into account the variability across Europe and figures 
extracted from the World Health Organization (WHO) mortality 
database,14 one can estimate for the European Union that 60% 
to 80% of liver-related mortality is due to excessive drinking.15 
According to WHO, morbidity attributable to alcohol in devel-
oped countries accounts for 10.3% of disability adjusted life 
years and comes second only to that of tobacco (11.7%). Within 
this figure, liver cirrhosis is responsible for 70% to 80% of the 
directly recorded mortality from alcohol. In 2010, alcoholic liver 
cirrhosis was responsible for 493,300 deaths (47.9% of all liver 
cirrhosis deaths), representing 0.9% of all deaths regardless the 
cause (0.7% of all deaths of women and 1.2% of all deaths of 
men), and 80,600 deaths (14,800 deaths of women and 65,900 
deaths of men) were attributable to alcohol-related liver cancer.4 
Apart from mere mortality figures, harmful alcohol consump-
tion is the second most common indication for liver transplan-
tation, accounting for approximately 40% of all primary liver 
transplants in Europe and about 25% in the United States.16 
Besides its remarkable health impact, this huge disease burden 
has an economic impact of about 125 billion Euros annually in 
Europe, accounting for 1.3% of the gross domestic product.17 
SPECTRUM AND PATHOPHYSIOLOGY OF ALD
Above a certain quantity, alcoholic consumption can elicit 
a spectrum of liver lesions among which steatosis is present in 
nearly all drinkers who consume in excess of 40 g/day regu-
larly. Beyond fatty liver, ALD comprises a continuum of partly 
Table 1. Alcohol-Associated Somatic and Mental Diseases
Acute intoxication (apnea, aspiration of gastric content)
Alcohol use disorders
Gastrointestinal tract, pancreas and liver
    • Alcoholic liver disease
    • Alcoholic pancreatitis
    • Cancer of the upper digestive tract (oral cavity, pharynx, 
       hypopharynx, pharynx, esophagus)
    • Motility disorders (esophagus, gastroesophageal reflux, gastric emptying, diarrhea)
    • Mucosal damage (including hemorrhagic gastritis)
    • Lactose intolerance
    • Colorectal cancer
Metabolic disorders
    • Hypoglycemia 
    • Hyperlipoproteinemia
    • Hyperuricemia (including gout) 
    • Porphyria 
    • Hyperferritinemia
Fetal alcohol syndrome
Cardiovascular disease
    • Cardiomyopathy
    • Arrhythmia (including atrial fibrillation)
    • Arterial hypertension
Alcoholic myopathy
Alcoholic osteopathy
Neurological and psychiatric disorders
    • Peripheral neuropathy
    • Dementia
    • Cerebellar atrophy with dyskinesia
    • Depression (including suicide)
Trauma
    • Bone fractures
    • Subdural hematoma
Breast cancer
Infections
    • Endocarditis 
    • Viral hepatitis 
    • Sepsis
    • Tuberculosis
Skin disease
    • Psoriasis   
    • Teleangiectasias
    • Spider angiomas 
    • Rhinophyma 
    • Palmar erythema
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overlapping liver abnormalities with variable degrees of inflam-
mation and progressive fibrosis in 10% to 35% of alcoholics, 
and liver cirrhosis in approximately 10% to 15% of heavy 
drinkers (Fig. 1).18 A great concern is the rising incidence of he-
patocellular carcinoma (HCC) which evolves in approximately 
1% to 2% of alcoholic cirrhotics per year.19 While steatosis and 
inflammation are reversible upon abstinence, and probably also 
fibrosis below the level of cirrhotic transformation, severe alco-
holic steatohepatitis (ASH), decompensating cirrhosis and HCC 
have a grave prognosis. 
The cellular and molecular mechanisms of ALD pathogenesis 
are still incompletely understood but seem to be related to a 
complex interaction between behavioral, environmental and 
genetic factors. The histological hallmarks of ALD, steatosis, 
inflammation and fibrosis are the result of interrelated and con-
secutive pathophysiological events in the context of continuous 
alcohol exposure. A pivotal component in the evolution of ALD 
is the direct toxicity of the first metabolite of alcohol degra-
dation, acetaldehyde (AA).20 Two major enzyme systems can 
metabolize alcohol to AA via oxidative degradation, of which 
alcohol-dehydrogenase is the system primarily responsible for 
the processing of lower amounts of alcohol. It is located in the 
cytosol and cannot be upregulated upon demand. In contrast, 
cytochrome P450 2E1 (CYP2E1) located in microsomes is induc-
ible and can be upregulated 10- to 20-fold in heavy drinkers.21 
Both enzyme systems generate AA, a highly reactive toxic and 
mutagenic metabolite, by which they not only degrade ethanol 
(and other organic substances), but also contribute to alcohol-
related toxicity (Fig. 2). Apart from generating AA, CYP2E1 also 
contributes of oxidative damage by the formation of reactive 
oxygen species (ROS) such as superoxide anion and hydrogen 
peroxide. Hepatic CYP2E1 activity in humans may already in-
Healthy liver
Steatosis/fibrosis
alcoholic steatohepatitis Liver cirrhosis Liver cancer
Alcohol Alcohol Alcohol
90%-100% of alcoholics have steatosis
10 -35% show alcoholic hepatitis
8 -20% develop cirrhosis
1 -2% of cirrhotics/year develop HCC
%
%
%
Fig. 1. The progression for alcoholic liver injury to steatosis with scarring, inflammation and architectural distortion leading to cirrhosis. As a 
complication of cirrhosis, hepatocellular carcinoma may occur. However, only a minority of patients with alcoholic steatosis progress to severe 
liver injury.
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Fig. 2. Hepatic metabolism of etha-
nol by enzymes ADH, CYP2E1 and 
catalase. Each enzyme generates ac-
etaldehyde, a toxic and mutagenic 
metabolite of ethanol. While ADH 
is metabolically stable regardless of 
the alcohol challenge and catalase 
is irrelevant with respect to its role 
in hepatic alcohol degradation, 
CYP2E1 is inducible and contributes 
most to acetaldehyde production 
during heavy alcohol consumption.
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crease following the ingestion of only 40 g of ethanol/day for 
1 week.22 In rodents, the induction of CYP2E1 correlated with 
NAD phosphate oxidase activity, the generation of hydroxyethyl 
radicals, lipid peroxidation and the severity of hepatic damage, 
all of which could be prevented by the CYP2E1 inhibitor clome-
thiazole.23,24 Importantly, AA is also a powerful carcinogen in 
experimental animals and in humans, and considered an impor-
tant reason for the association of certain cancers with alcohol 
consumption.25
The initial liver lesion in alcoholics is steatosis which oc-
curs in literally all heavy drinkers as a result of disrupted lipid 
turnover.26 Above all, decreased fatty acid oxidation, increased 
fatty acid and triglyceride synthesis, increased fat entry into 
the liver by fatty acid mobilisation from peripheral fat stores 
and via chylomicrons from the intestine are instrumental. Fur-
thermore, increased lipogenesis by dysregulation of steatogenic 
enzymes and transcription factors including sterol regulatory-
binding protein 1c, peroxisome proliferator-activated receptor 
a, and microsomal triglyceride transport protein are involved. A 
more recent revelation is the potential role of protein enzymes 
involved in lipid processing such as PNPLA3 and TM6SF2 for 
which genetic variants of the coding genes were found associ-
ated with ALD (see below). Whether and how alcohol consump-
tion affects the function of these enzymes, however, is still 
unclear.
Similar to non-ASH, inflammation can occur as an important 
feature in alcoholic steatosis resulting in ASH, and evolve as 
a major driving force for fibrogenesis leading to fibrosis, cir-
rhosis and most likely, hepatocarcinogenesis. Histologically, 
ASH is characterized by variable degrees of steatosis, a typical 
inflammatory infiltrate consisting of predominantly polymor-
phonuclear (PMN) cells, centrilobular hepatocyte ballooning, 
Mallory-Denk inclusion bodies, and a “chicken wire”-like fibro-
sis network.27 A key pathogenic pathway in this stage is the gut-
liver axis. Thus, alcohol ingestion increases gut permeability and 
promotes the translocation of endotoxins from Gram negative 
bacteria such as lipopolysaccharides (LPS) into the portal blood-
stream to reach Kupffer cells which, upon binding of LPS to 
the endotoxin receptor CD14 activate the MyD88-independent 
signaling pathway through TLR4, with consecutive production 
of proinflammatory cytokines such as tumor necrosis factor a 
that contribute to hepatocellular damage.28-30 Additional cyto-
kines and chemokines involved in the activation/recruitment of 
inflammatory and mesenchymal cells contributing to inflam-
mation and fibrotic repair processes in ALD are interleukin (IL)-
1, IL-8, and IL-17, osteopontin, chemokine (CXCL)1, CXCL4, 
CXCL5, and CXCL6.30-32 These proinflammatory sequelae are 
particular prominent in patients with ASH.
The key lesion in chronic liver disease is fibrosis that, in es-
sence, resembles the process of excessive wound healing as a 
result of increased fibrogenesis and decreased fibrolysis. In pro-
gressive fibrosis, liver parenchyma is replaced by excess extra-
cellular matrix produced by activated hepatic stellate cells (HSC) 
and myofibroblasts (MFB), resulting in a distorted liver architec-
ture and progressive functional impairment.33 Various triggers 
can activate liver macrophages (Kupffer cells) and other inflam-
matory cells which leads to the production of the profibrogenic 
cytokines platelet-derived growth factor and transforming 
growth factor-β1 which can stimulate HSC/MFB to produce 
collagens, noncollagenous glycoproteins, proteoglycans, and 
glycosaminoglycans up to 10-fold compared to normal liver 
tissue. Here, the fibril forming collagens type I and III make up 
for >80% of total liver collagen. In turn, matrix-degrading en-
zymes termed matrix-metalloproteinases are downregulated by 
their corresponding tissue inhibitors.33 In ALD, HSCs/MFBs can 
be stimulated by AA,34 ROS,35 leptin,36 endocannabinoids37 and 
lipid peroxides.38
The most worrisome complication of ALD is HCC, and the 
vast majority of HCCs develops on the background of alcoholic 
cirrhosis.39 Besides cirrhotic transformation as a precancerous 
condition, a number of pathophysiological aspects are specific 
to alcohol-associated HCC. An important trigger of tumor de-
velopment is AA, which is not only a toxin, but also a highly 
reactive mutagen that forms stable DNA adducts, causes point 
mutation, sister chromatid exchanges, inhibits DNA repair, and 
via induced CYP2E1, activates pro-carcinogens to carcinogens.9 
Other molecular mechanisms include epigenetic modifications 
from alcohol by altering DNA methylation. Indeed, epigenetic 
silencing of hypermethylated tumor suppressor genes and acti-
vation of oncogenes via hypomethylation correlate with surviv-
al in human HCC including patients with alcoholic cirrhosis.40 
Recent studies have shed some light on the pathogenesis of 
ASH. Here, failure of the liver to regenerate the hepatocellular 
mass seems to play a major role. Explants from ASH patients 
that underwent liver transplantation revealed that nonre-
sponders to medical therapy had reduced hepatic expression of 
liver regeneration-related cytokines and the lack of proliferative 
hepatocytes.41 This observation was further confirmed by oth-
ers, which showed that presence of proliferating hepatocytes in 
alcoholic hepatitis (AH) is associated with a better prognosis.42 
In addition, a massive expansion of liver progenitor cells (LPCs) 
called “ductular reaction” is often observed in AH patients, but 
these LPCs fail to differentiate into mature hepatocytes and cor-
relate positively with severity of liver disease and short-term 
mortality in these patients.43 
Experimental ALD
Studying ALD experimentally has been extremely difficult 
since no animal model exists that closely mirrors all relevant 
features of severe ALD in humans or only pivotal elements of 
it.44 Rodents are notoriously resistant to the hepatotoxic effects 
of alcohol due to species-related differences in alcohol metabo-
lism, and rats or mice only develop significant chronic liver 
injury when exposed to alcohol in combination with a second 
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toxin (e.g., carbon tetrachloride and thioacetamide) or major 
dietary manipulations (e.g., choline/methionine deficiency) that 
still do not produce a histological picture that fully models that 
of human ALD.45 The experimental setup that produces liver le-
sions most similar to those in humans is the intragastric feeding 
model, or Tsukamoto-French model in which continuous infu-
sion of alcohol-containing food via a surgically-implanted gas-
tric tube results in typical alcohol-induced liver injury including 
steatohepatitis, fibrosis and microscopic lesions such as balloon-
ing, Mallory-Denk bodies and neutrophilic inflammatory infil-
tration.46 The lack of a suitable animal model has been a signifi-
cant impediment to more deeply study ALD experimentally, and 
is one of the reasons for the suboptimal research on novel bio-
markers retrieved from human omics studies (vide infra). Recent 
advances, such as the National Institute on Alcohol Abuse and 
Alcoholism model of ALD, that combine binge drinking pat-
terns with chronic alcohol exposure may pave the way for more 
suitable models.47 This can be promising when combined with 
novel technologies to design genetically modified rodents such 
as with the CRISPR/Cas9 technique to overcome species-related 
differences in alcohol susceptibility.48
FACTORS MODULATING PROGRESSION OF ALD
Significant ALD with progressive fibrosis and cirrhosis devel-
ops only in a minority of heavy drinkers suggesting that apart 
from alcohol itself, modifying variables exist that modulate the 
individual susceptibility to the toxic effects of alcohol. ALD is 
considered a complex disease in which numerous factors inter-
act to allow for liver disease to occur. These factors are referred 
to as environmental (exogenous) or host (inherent) disease mod-
ifiers which partly explain the large inter-individual variability 
in the likelihood to develop ALD. Much progress has been made 
in our understanding of how these factors are entangled as out-
lined below.
1. Environmental factors
The development of ALD requires heavy alcohol drinking, 
and consensus exists that there is a clear dose-relationship be-
tween the amount of alcohol and the likelihood of its develop-
ment.49,50 According to the Dionysos Study from Italy the risk 
of developing alcoholic cirrhosis is highest in those with a daily 
consumption of above 120 g of pure alcohol per day.51 Drinking 
patterns were suggested as modifier of ALD, such as drinking 
with meals appeared to confer less risk than consuming alcohol 
outside separately. Regarding the type of alcoholic beverage it 
was suggested that wine drinking is associated with a lower risk 
of ALD;52 however, scientific persuasion prevails that it is rather 
the amount of alcohol contained in certain alcoholic beverages 
than the nonalcoholic contents, and that the effect of different 
beverages on ALD risk are rather related to lifestyle and dietary 
factors.53 Coffee drinking appears to protect alcohol-related liver 
injury with people drinking four or more cups a day having 
one-fifth of the risk of developing cirrhosis as non-coffee drink-
ers.54 In turn, cigarette smoking increases the risk of alcoholic 
cirrhosis with smokers of ≥1 pack daily showing a 3-fold higher 
risk than nonsmokers.55
Coinfection with viral hepatitis B and C is also recognized as 
an important promoter of ALD, although the clear distinction 
between viral hepatitis worsened by alcohol, or vice versa, is 
often difficult to make and relies mainly on the predominant 
histology lesion prevalent in a patient with both conditions. The 
most abundant data exist for the interaction between alcohol 
and chronic hepatitis C for which numerous population-based, 
cross-sectional and cohort studies have demonstrated a higher 
prevalence of alcohol abuse among hepatitis C virus (HCV)-
infected subjects, and a higher prevalence of HCV antibodies 
among drinkers.56 In a large study including 800 patients with 
chronic HCV infection, Monto et al.57 showed that those who 
drink alcohol in excess of 50 g/day have a significantly higher 
risk of advanced fibrosis than those who drink less or not at all. 
Mechanistically, published data suggest that alcohol accelerates 
the progression of hepatitis C-related liver disease via increased 
oxidative stress, cytotoxicity, immune dysfunction and reduc-
tion of response to antiviral treatment. Similar mechanisms are 
believed to be in place regarding hepatitis B virus-infected sub-
jects, although the data regarding the latter is less abundant.58
Overweight has been consistently associated with an in-
creased risk of developing alcohol-related fibrosis and cirrhosis 
potentially reflecting a synergistic interaction between alcohol 
and lipotoxicity from steatosis as a consequence of obesity.59-61
2. Host genetic factors
Several observations indicate an at least partial genetic back-
ground of ALD and its progression. Persuasive evidence for a 
genetic background of ALD stems from a twin study undertaken 
in a population of 15,924 male twin pairs in which the concor-
dance for alcohol-related cirrhosis was found three times higher 
in monozygotic twins than in dizygotic twins.62 Another strong 
genetic modifier is gender: women carry a greater risk of devel-
oping alcohol-related cirrhosis, likely attributable to hormonal 
effects on oxidative stress and inflammation,63 differences in 
expression patterns of alcohol-metabolizing enzymes,64 and 
a smaller distribution volume of alcohol in women and, thus, 
higher tissue levels of alcohol exposure.65 
In the United State white Hispanic men and women reveal 
a higher risk for alcoholic cirrhosis compared with black and 
Caucasian white men and women,66 and present with alcohol-
related cirrhosis up to 10 years earlier than their Caucasian 
counterparts.67 However, besides constitutional differences in 
alcohol metabolism these differences could very well be related 
to cultural differences, amounts and types of alcohol consumed, 
dietary intake, socioeconomic status, and access to health care.
After an avalanche of relatively small candidate gene studies 
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investigating hypothesis-based single nucleotide polymorphisms 
within genes considered relevant for ALD phenotypes generated 
data which could not be replicated, recent candidate gene stud-
ies and genome-wide scans have identified genetic risk factors 
which robustly associate with ALD and its complications. These 
data shed new light on yet unknown pathophysiological aspects 
of ALD, and potentially open the field for better prevention, 
screening and the development of novel therapies. The first and 
most robustly confirmed risk locus for ALD is a sequence varia-
tion within the gene coding for patatin-like phospholipase en-
coding 3 (PNPLA3, rs738409C>G, I148M) which was found to 
modulate the evolution of steatosis, necroinflammation, fibrosis 
and HCC in alcoholics.68,69 The genetic risk of ALD has also 
been studied on a genome-wide level by two recent studies in 
alcoholic cirrhosis70 and alcoholic hepatitis.71 Both studies con-
firmed PNPLA3 rs738409 as a strong genetic risk locus for both 
alcoholic cirrhosis and AH with genome-wide significance, and 
for cirrhosis, two additional, hitherto unknown loci were identi-
fied: membrane bound O-acyltransferase domain containing 7 
(MBOAT7) (P=9.25×10–10) and transmembrane 6 superfamily 
member 2 (TM6SF2). Both PNPLA3 and TM6SF2 are implicated 
in hepatic lipid trapping, while MBOAT7 mediates the transfer 
of fatty acid between phospholipids and lysophospholipids, a 
potent driver of hepatic inflammation.69 However, the func-
tional implication of the mutant PNPLA3 variant is not yet fully 
understood, partly due to a lack of experimental translation in 
animals, but a homology model of the patatin domain derived 
from a plant protein structure suggests that the isoleucine to 
methionine substitution at position 148 in rs738409 is stereo-
typically close to the catalytic dyad of the protein (Fig. 3).72 This 
substitution likely results in impaired accessibility of PNPLA3 
substrates, i.e., triglycerides, to the catalytic serine moiety, a 
theory supported by subsequent molecular dynamic simula-
tions.73 This would result in a reduction in hydrolytic function, 
“lipid trapping” and the accumulation of fat.
CLINICAL MANAGEMENT OF ALD
1. Diagnostic evaluation
In most cases, ALD is a clinically silent disease with little or 
no symptoms in patients with early ALD and in patients with 
compensated cirrhosis. Thus, diagnosis depends highly on clini-
cal suspicion, various laboratory tests and invasive or nonin-
vasive techniques.74 In some patients with early ALD stigmata 
of alcohol abuse such as bilateral parotid gland hypertrophy, 
muscle wasting, malnutrition, Dupuytren’s sign, and signs of 
peripheral neuropathy may be present, but more often patients 
are entirely asymptomatic and reluctant to openly admit that 
their drinking behavior may be the reason of their liver abnor-
malities. On physical examination of cirrhotic patients, liver-
typical skin signs include gynecomastia, spider angiomata, pal-
mar erythema, and smooth tongue. Moreover, jaundice, hepatic 
encephalopathy, ascites and pedal edema may also be visible 
at first glance in patients with end-stage liver disease. The di-
agnosis of ALD is frequently suspected upon documentation of 
excess alcohol consumption (>40–50 g/day) and the presence 
of clinical and/or biological abnormalities suggestive of liver 
injury. However, on taking the medical history one needs to be 
aware that self-reported alcohol consumption is often under-re-
ported and that quantification of alcohol consumption is at best 
semi-quantitative.75 Past complications of liver cirrhosis such as 
gastrointestinal bleeding, ascites, jaundice episodes, or accidents 
due to encephalopathy or drunkenness reported by the patient 
or an accompanying person are important diagnostic informa-
tion. 
Laboratory tests such as mean corpuscular volume of red 
blood cells, γ-glutamyltransferase (GGT) and aspartate amino-
transferase (AST), IgA, can indicate early ALD while a decrease 
of albumin, increased international normalized ratio (INR), 
elevated bilirubin level and/or a low platelet count are signs of 
advanced ALD. Many heavy drinkers also reveal elevated levels 
Asp166
IIe148
Ser47
TG
TG
Met148
Asp166
Ser47
Fig. 3. Structural modifications at 
the PNPLA3 rs738409 locus (I148) 
affect the substrate binding groove 
rather than the catalytic center of 
the protein. Substituting methionine 
(Met) for isoleucine (Ile) at position 
148 of the PNPLA3 protein reduces 
accessibility for substrates (e.g., tri-
glycerides) and thus results in a loss 
of function.
Stickel F, et al: Update Alcoholic Liver Disease  179
of triglycerides and uric acid, the latter often associated with 
gout attacks.76 Alcohol-specific markers include carbohydrate 
deficient transferrin and ethyl-glucuronide,77 however, sensitiv-
ity of the former is limited as many drinkers remain undetected 
due to normal levels.78 Clinically, GGT is the most frequently 
used marker to detect previous alcohol consumption, however, 
it lacks specificity and can also rise due to other etiologies.79 In 
patients with ALD, the AST/alanine aminotransferase (ALT) ratio 
typically is >1, and may be >2 in patients with AH. However, it 
can also be found in patients with advanced cirrhosis regardless 
of the etiology.
Liver biopsy is not routinely advised in patients with early 
or cirrhotic stages of ALD if clinical, analytical and imaging 
data are undisputed.74,80 However, a liver biopsy may be useful 
to rule out nonalcoholic etiologies or when noninvasive tools 
fail to obtain a clear result. Biopsies are mostly performed per-
cutaneously, but may require a transjugular route in patients 
with impaired coagulation due to a low platelet count and/or 
a prolonged prothrombin time, or when portal pressure shall 
be measured in addition. Sometimes, a liver biopsy can help 
to convince a patient of the cause of their liver abnormalities, 
and to persuade patients to change their drinking behavior, al-
though this line of reasoning is not entirely scientific.81 A clear 
indication exists in patients with aggressive forms of ALD such 
as ASH requiring specific therapies (e.g., corticosteroids and/or 
pentoxifylline) and in patients with other cofactors suspected 
of contributing to liver disease, e.g., coexisiting viral hepatitis 
or iron overload.74 The typical findings in patients with ALD 
include steatosis, hepatocellular damage (ballooning and/or 
Mallory-Denk bodies), inflammatory infiltrates composed of 
PMN cells predominating in the lobules, and a variable degree 
of fibrosis and lobular distortion that may progress to cirrhosis 
(Fig. 4).82 
For the assessment of liver fibrosis in patients with ALD, 
there are noninvasive methods including serum markers and 
liver stiffness measurement, however, none has been suffi-
ciently validated in ALD. Simple tests that rely on AST levels, 
such as AST to platelet ratio index and AST/ALT ratio, are not 
particularly useful in ALD due to the higher AST values in such 
patients that do not necessarily correlate with severe fibrosis.83 
Single variables such as hyaluronic acid are useful to confirm 
advanced fibrosis or cirrhosis, but are neither specific nor help-
ful in early diagnosis of ALD. Branded panels such as FibroTest, 
FibroMeter and Enhanced Liver Fibrosis score have not been 
sufficiently validated for ALD. Common to all these tests is that 
they are useful to distinguish between mild and severe fibrosis, 
but have limited value in intermediate stages of fibrosis.83 
Transient elastography (Fibroscan®) is widely established to 
assess fibrosis in patients with chronic liver disease and has 
recently been approved by the Food and Drug Adminstration 
(FDA). In patients with ALD, liver stiffness correlates with the 
stage of fibrosis,84 but elevated values need to be interpreted 
with caution in patients with ALD and AST serum levels >100 
U/L due to the possibility of falsely elevated liver stiffness as 
a result of inflammation-related liver congestion. Moreover, 
recent alcohol consumption can also increase liver stiffness, 
perhaps related to the vasodilatory effects of alcohol.85 Imaging 
techniques can also be used to assess the severity of ALD. Ultra-
sonography, magnetic resonance imaging (MRI), and computed 
tomography are useful to detect steatosis, advanced fibrosis/
cirrhosis as well as signs of portal hypertension.86 Moreover, 
they are useful for the screening and assessment of complica-
tions such as ascites and portal vein thrombosis. Among those 
methods, ultrasound is the most widely used due to its low cost. 
MRI and MR spectroscopy are reliable tools for quantifying ste-
atosis but their use is limited by high cost.87 Transient elastog-
raphy (Fibroscan®) offers a software update to quantify liver fat 
termed Controlled Attenuation Parameter (CAP function) as a 
significantly cheaper alternative;88 however, comparative studies 
are lacking.
A distinct entity represents severe ASH as a relatively rare but 
serious complication of ALD characterized by new onset jaun-
dice and/or ascites in heavy drinkers with or without underlying 
advanced ALD. Population based studies estimate approximately 
4.5 hospitalizations for AH per 100,000 persons each year, with 
a slight male predominance, and wide variation across coun-
tries.89 Prospective studies assessing the incidence, risk factors 
and clinical features of AH are clearly needed as it is assumed 
that a large proportion of ASH cases remain unrecognized and 
therefore not appropriately treated. 
Patients with ASH typically present with rapidly progressive 
jaundice, often accompanied by fever, abdominal discomfort, 
anorexia, and weight loss. In severe cases, patients present with 
Steatosis Ballooning Fibrosis
Fig. 4. Typical appearance of alcoholic cirrhosis showing three prom-
inent features of alcoholic liver disease, i.e., fibrosis (blue arrow), ste-
atosis (red arrow) and ballooning (yellow arrow). Significant inflam-
mation is often not seen but consists of neutrophilic and lymphocytic 
infiltrates when visible (chromotrope anilin-blue stain; magnification 
×100).
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ascites, encephalopathy, hepatorenal failure and/or variceal 
bleeding. Patients with severe AH frequently present with the 
clinical picture of a so-called systemic inflammatory syndrome 
characterized by tachycardia, leucocytosis, and elevated C-reac-
tive protein and procalcitonin probably due to sterile inflamma-
tion and/or or concomitant infections.90 In some patients, ASH 
is the first manifestation of a previously unnoticed ALD, in oth-
ers it can be a complication of cirrhosis. 
Serum liver enzyme levels are often elevated 2- to 6-fold, and 
lower that in acute viral hepatitis, characteristically with AST el-
evation exceeding that of ALT related to an alcohol-induced de-
ficiency of pyridoxal 5’-phosphate (vitamin B6).
91 Most patients 
with AH have some degree of coagulopathy with an increased 
INR impaired liver function, and/or low platelet numbers due to 
splenomegaly from portal hypertension or direct alcohol toxic-
ity on platelets. Particularly severe is the development of kidney 
failure due to hepatorenal syndrome or acute tubular necrosis 
which identifies the subgroup with the worst prognosis.92
Of note, patients with ALD can also show an episode of jaun-
dice and liver decompensation due to other reasons than AH 
such as in sepsis, biliary obstruction, diffuse HCC, drug-induced 
liver injury or gastrointestinal bleeding. Infections, particularly 
spontaneous bacterial peritonitis, must be ruled out as they can 
present with similar clinical findings (abdominal pain, fever, 
leukocytosis), and because they are a contraindication to specific 
therapy with corticosteroids. This is why a correct diagnosis and 
detailed work-up is so important and advocates a liver biopsy 
as set forth in recent clinical practice guidelines.74,80,93 Due to 
frequent coexisting ascites and/or coagulopathy a transjugular 
route is often preferred which also allows for the measurement 
of hepatovenous pressure gradient as a surrogate marker of por-
tal pressure. Serologic evaluation for viral hepatitis and imaging 
with Doppler ultrasound to exclude biliary or vascular disorders 
and HCC are recommended.
Several models have been developed to help predict outcomes 
of patients with AH and to guide therapy (Table 2). The most 
widely used is the Maddrey et al.’s94 discriminant function (DF) 
introduced already in 1978, which is calculated as 4.6×(pro-
thrombin time/patient–prothrombin time/control)+serum bili-
rubin. A DF value ≥32 is indicative of a high risk of short-term 
mortality (35% at 1 month) and selects patients for corticoste-
roid therapy. Additional predictive models include the Model for 
End-Stage Liver Disease (MELD), the Glasgow alcoholic hepatitis 
(GAH) score, the Age, Bilirubin, INR, Creatinine (ABIC) score.95-97 
The MELD is a statistical model that is calculated using serum 
bilirubin, creatinine, and INR, which is able to predict 30- and 
90-day mortality in patients with AH with accuracy similar to 
the DF.95,97 The GAH score incorporates age, serum bilirubin, 
blood urea nitrogen, prothrombin time, and peripheral white 
blood cell count, and accurately predicts short- (28 days) and 
midterm- (84 days) mortality. The ABIC uses age, bilirubin, INR, 
and creatinine to estimate a 90-day risk of mortality, and can 
categorize patients into low (0%), intermediate (30%), and high 
(75%) risk of death. The MELD has been evaluated in the U.S. 
cohorts, the GAH in populations from the United Kingdom, and 
the ABIC in Spain.98-100 An important innovation was the cre-
Table 2. Scores for Assessing AH Severity
Score Calculator Interpretation Remarks
DF DF=4.6 (patient’s PT–reference PT)+total bilirubin (mg/dL) Poor prognosis when ≥32; 
defines threshold for  
corticosteroid therapy
Most widely used score in 
clinical studies
No consideration of kidney 
function
MELD MELD=3.8×log(bilirubin [mg/dL])+11.2×log(INR)+9.6×log(creatinine [mg/dL])+6.4 Poor prognosis when ≥18 Designed for listing patients 
for liver transplant; perfor-
mance comparable with DF
ABIC (age×0.1)+(serum bilirubin×0.08)+(serum creatinine×0.3)+(INR×0.8) Low risk ABIC ≤6.71
Intermediate risk when  
ABIC >6.71 and ≤9.0
High risk when ABIC >9.0
Not validated outside Spain
Not designed to guide therapy 
for patients with AH
GAH 1 2 3 Poor prognosis if score >8 
(calculated on day 1 and 7 
of hospitalization)
Requires more variables than 
the other scoresAge <50 ≥50 -
Leucocytes <15 ≥15 -
Urea (mmol/L) <5 ≥5 -
INR  <1.5 1.5–2.0   >2.0
Bilirubin (mg/dL)  <7.3   7.4–14.6 >14.6
AH, alcoholic hepatitis; DF, discriminant function; PT, prothrombin time; MELD, Model for End-Stage Liver Disease; INR, international normal-
ized ratio; ABIC, Age, Bilirubin, INR, Creatinine; GAH, Glasgow alcoholic hepatitis. 
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ation of the Lille model which assesses the patients’ prognosis 
as per response to corticosteroid therapy. The Lille model mea-
sures the change in serum bilirubin after one week of cortico-
steroid incorporating age, albumin, creatinine, and prothrombin 
time.101 In those not responding to corticosteroids within 7 days 
of treatment clinical practice guidelines recommend cessation 
of corticosteroids since the risks, i.e., severe infections, with 
continued therapy outweigh the benefits. A large multicentric 
study recently developed a histological scoring system, Alco-
holic Hepatitis Histological score (AHHS), capable of predicting 
short-term survival in AH patients. AHHS computes fibrosis 
stage, PMN infiltration, type of bilirubinostasis and presence 
of megamitochondria which are independently associated with 
patients’ survival in a semiquantitative manner and allows for 
stratification of patients into low, intermediate, or high risk for 
death within 90 days.102 
THERAPY OF PATIENTS WITH ALD
1. Achieving abstinence
The backbone of the treatment of patients with ALD is the 
achievement and maintenance of alcohol abstinence since the 
efficacy of medical treatments for ALD is limited in those who 
continue to drink. As many patients with ALD display clinical 
criteria of AUD, a generic term covering a wide variety of drink-
ing behaviours and their consequences often labeled as “heavy 
drinking,” “harmful drinking,” “alcohol misuse/abuse,” “problem 
drinking” and “alcohol dependence” defined by the fourth edi-
tion of the DSM criteria (DSM-IV)103 and the 10th edition of the 
ICD criteria (ICD-10).104 Both systems describe drinking behavior 
leading to physical, psychosocial and mental disadvantages 
requiring therapeutic intervention. Clinical research efforts have 
focused on treating AUD in ALD patients and current consensus 
is that a combination of psychosocial interventions, pharmaco-
logical therapy and medical management seems to be the most 
effective management strategy for AUD patients with ALD.105 
Pharmaceutical approaches to treat AUD are available, how-
ever, their safe use in patients with ALD has only been tested 
for a few drugs. So far, only baclofen has a published track 
record that confirms both efficacy and safety in several open 
label trials106,107 and one randomized controlled trial,108 while 
the FDA-approved AUD drugs disulfiram and naltrexone are 
contraindicated in ALD patients due to possible hepatotoxicity. 
Nalmefene, a μ- and δ-opioid receptor antagonist and κ-opioid 
receptor partial-agonist, was recently approved for the treat-
ment of AUD by the FDA, but safety data in patients with ALD 
is limited since patients with advanced ALD were excluded from 
the registrations trial.109
Assigning the appropriate treatment for each AUD category 
in ALD patients requires careful assessment of patients in the 
context of integrated concepts in which physicians, addiction 
specialists and psychosocial support providers jointly treat ALD 
patients to achieve abstinence, or at least substantial risk reduc-
tion. 
2. Nutritional support
While patients with early ALD usually are adequately nour-
ished, those with advanced ALD, and AH in particular, reveal 
significant clinical signs of malnutrition. Up to 60% of alcohol-
ics with cirrhosis and literally all hospitalized alcoholic cirrhotics 
reveal some degree of malnutrition which aggravates along with 
the severity of ALD.110 And although alcohol provides 7.1 kcal/g 
of energy which is more than that of carbohydrates (4.1 kcal/g), 
patients with ALD often present with severe primary and sec-
ondary malnutrition, and particularly, protein energy malnutri-
tion.110 Therefore, adequate nutritional support is recommended 
in recent guidelines.74,80,111 The causes of primary malnutrition in 
ALD include: (1) low dietary intake due to imbalanced diet com-
position or replacement of food calories by those derived from 
alcohol; (2) lack of appetite related to dysgeusia, esophagitis, 
gastritis, poor dental status; (3) lack of palatability of diets low 
in sodium; (4) malabsorbtion because of diarrhea, exogenous 
pancreatic insufficiency; and (5) complications of liver disease, 
e.g., ascites, hepatic encephalopathy. Besides inadequate dietary 
intake, heavy alcohol consumption can also lead to profound 
interactions with the metabolism of numerous micronutrients. 
Uptake and bioavailability of a wide array of water- and fat-
soluble vitamins as well as trace elements are influenced by 
concomitant heavy alcohol and can cause clinical syndromes 
unrelated to ALD per se, but which should be remembered when 
treating patients (Table 3).
While clinical trials failed to demonstrate a benefit from par-
enteral nutritional therapy in ALD, numerous studies provided 
robust evidence for a benefit from enteral nutritional support 
on several surrogate markers of nutritional status such as nitro-
gen balance, anthropometric variables and survival.110 Several 
studies suggested a benefit from supplementing diets with the 
branched-chain amino acids valine, leucine and isoleucine to 
maintain adequate protein intake without worsening of hepatic 
encephalopathy in protein-intolerant cirrhotic patients,112,113 but 
a recent Cochrane analysis of 37 clinical trials not restricted to 
ALD found only weak evidence supporting the routine use of 
parenteral nutrition, enteral nutrition, or oral nutritional supple-
ments in patients with liver disease. Benefits of nutritional ther-
apy were limited to weak endpoints such as improved bilirubin 
levels and a better nitrogen balance in patients actively treated 
with nutrition, but not on prolongation of survival.114
From a practical point of view, current guidelines recom-
mend a dietary intake of 1.2 to 1.5 g of protein/kg and 35 to 
30 kcal/kg body weight, frequent meals including a nighttime 
snack.74,80,111 Considering the numerous micronutrient deficien-
cies in advanced ALD, adequate supplementation thereof is also 
advised. 
In patients with severe AH the prevalence of malnutrition 
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reaches 100% and a significant correlation of malnutrition with 
short- and long-term survival has been demonstrated.115 While 
earlier randomized trials in relatively small patient numbers 
reported a possible benefit of vigorous nutritional support in 
patients with alcoholic cirrhosis and AH, including on improved 
survival,116 only one recent randomized controlled trial in 136 
patients with biopsy-proven AH studied a combination of in-
tensive enteral nutrition via feeding tube plus methylpredniso-
lone against conventional nutrition plus methylprednisolone 
(controls).117 The primary endpoint was 6-month survival, and 
secondary end points comprised mortality at 1 month, rates of 
infection, and occurrence of hepatorenal failure at 6 months. 
Survival in both groups was similar (44.4% vs 52.1% in con-
trols, p=0.406), and the feeding tube was poorly tolerated. How-
ever, patients with a calorie intake of less than 21.5 kcal/kg/
day were more likely to die emphasizing the need for adequate 
nutrition.
3. Pharmaceutical therapy
Despite the prominent burden of ALD on liver-related mor-
bidity and mortality, therapies that specifically target established 
ALD and/or fibrosis/cirrhosis are not available and very little 
progress has been made in this regard over the last decades in 
comparison to the tremendous advances in other liver diseases. 
For many, the therapeutic watchword has been “just stop drink-
ing” and interest of pharmaceutical companies and clinicians 
in developing and testing novel drugs to treat ALD has been 
low. So, numerous preparations are distributed which are at best 
harmless, but far from truly effective. 
Longest known and widely used is an extract of Silybum 
marianum (milk thistle) which contains silibinin as the biologi-
cally most active compound. The premier indication for silyma-
rin treatment is Amanita phalloides (death cup fungus) intoxica-
tion in which silymarin acts as a life-saving hepatoprotectant.118 
The popularity of silymarin products among patients with 
chronic liver disease was promoted by a clinical trial in 170 
patients with cirrhosis of various etiologies which demonstrated 
a significant survival benefit in those treated with silymarin.119 
Another multicenter trial in 200 patients with alcoholic cirrhosis 
treated with 450 mg silymarin daily did not confirm a benefit,120 
and a Cochrane systematic review of 13 randomized controlled 
trials found not benefit from silymarin treatment.121
The same fate is shared by data on propylthiouracil,122 col-
chicine,123 S-Adenosyl-L-methionine (SAMe),124 and polyenyl-
phosphatidylcholine125 which all proved no more effective than 
placebo in the treatment of ALD. 
1) Alcoholic steatohepatitis
A somewhat different situation is that of severe ASH in which 
therapeutic challenges reside in the restoration of liver synthetic 
function as well as reducing hepatic and systemic inflammation. 
The linchpin of AH treatment are abstinence, corticosteroids 
and intensive care addressing the complications of ASH such as 
renal failure and sepsis. 
Corticosteroids have been used in the treatment of ASH for 
more than 40 years.126 A meta-analysis from individual data 
from studies considered of high quality showed improved sur-
vival in patients with a high DF when treated with corticoste-
roids.127 The most studied formulation is prednisolone 40 mg 
daily for 4 weeks, with or without a taper after that period. The 
response to prednisolone can be assessed based on the change 
in bilirubin after one week of therapy and quantified using 
the Lille score, as outlined above.101 For those with a poor re-
sponse as indicated by a Lille score ≥0.45, stopping therapy can 
be considered, as these patients are not likely to benefit from 
continued corticosteroids and rather incur side-effects. Based 
on these data, expert practice guidelines recommend the use of 
corticosteroids in AH patients with a DF >32, and the European 
guideline advises cessation thereof should response after 7 days 
of treatment should be insufficient according to the Lille mod-
el.74,80
Numerous reports suggested a benefit of pentoxifylline (PTX), 
an orally absorbed nonselective phosphodiesterase inhibi-
tor approved for the treatment of intermittent claudication, 
Table 3. Micronutrients Affected by Heavy Alcohol Consumption and Corresponding Clinical Syndromes
Micronutrient Clinical syndrome
Vitamin A Night blindness, infertility
Thiamine Wernicke-Korsakoff encephalopathy, cardiomyopathie (Beri-Beri)
Folate Anemia, increase of cancer risk
Vitamin D Osteomalacia, osteopenia
Vitamin E Reduced antioxidative resistance
Niacine Pellagra, neuropsychiatric symptoms
Pyridoxalphosphat Anemia
Zink Wound healing problems, skin problems, immunodeficiency, diarrhea
Magnesium Muscle cramps, glucose intolerance
Selenium Myopathy, cardiomyopathy
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in reducing the development of the hepatorenal syndrome in 
patients with ASH.128 However, recent data from the Steroid or 
Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial, a large 
randomized-controlled trial of treatment of patients with severe 
AH with prednisolone or PTX, or their combination has raised 
doubts over the benefit of PTX in AH patients.129 Prednisolone 
alone reduced the risk of 28-day mortality, but no additional 
benefit derived from PTX. But the trial was underpowered to 
analyze the subgroup of patients with hepatorenal failure which 
may have resulted in a failure to detect a benefit in a specific 
group where PTX could have been of value. Similar results 
came from a similar trial, which however was again underpow-
ered for the subgroup of patients with hepatorenal syndrome.130 
N-acetylcysteine (NAC) is well-established in the treatment of 
fulminant hepatic failure due to paracetamol overdose,131 and 
improves transplant-free survival in early stage nonparacetamol 
acute liver failure.132 A recent randomized trial showed that the 
combination of NAC with prednisolone reduced 1-month mor-
tality (8% vs 24%) and the incidence of hepatorenal syndrome 
and infection.133 The favorable safety profile of NAC makes it 
a potential option, in combination with corticosteroids, for pa-
tients with severe disease.
4. Liver transplantation
ALD is among the most frequent indications for orthotopic 
liver transplantation (OLT) worldwide.16 In general, mortality 
and morbidity after LT in ALD patients is similar to patients 
with other etiologies, but the causes of death after transplan-
tation for ALD differ from those in non-ALD recipients.134 In 
particular, cardiovascular causes and de novo malignancies 
are more frequent in the patients transplanted for ALD both of 
which are associated with decreased survival.16,135 The combina-
tion of cardiovascular deaths and of new onset cancers of the 
aerodigestive tract in patients after OLT for ALD strongly sug-
gest a causal linkage with cigarette smoking, which is common 
among ALD transplanted patients. These data highlight a serious 
health risk for ALD patients after OLT and demonstrate the need 
for stringent clinical monitoring and intervention for tobacco 
use in the pre- and post-transplant periods.
OLT listing should be considered for patients who develop 
liver dysfunction corresponding to a Child-Pugh score ≥7 or 
MELD score ≥10, or clinical decompensation (ascites, variceal 
bleeding, or hepatic encephalopathy).93 
Most transplant programs require a 6-month period of absti-
nence before consideration for LT, mainly for two reasons: (1) 
to allow for recovery of liver function which may improve to 
the point that OLT is no longer necessary and (2) to reduce the 
risk of posttransplant recidivism, although its value for predict-
ing abstinence after OLT is poor.136,137 According the “6-month 
rule,” patients with AH are ineligible for OLT and die if they 
do not respond to corticosteroids. However, posttransplant 
outcomes including that of abstinence seem to be good for 
highly selected patients with severe AH unresponsive to medical 
therapy, as demonstrated by a recent French multicenter study 
in nonresponders to prior corticosteroid therapy.138 Mathurin 
et al.138 selected 26 patients with severe AH with a median Lille 
score of 0.88 indicating a high risk of short-term death for OLT 
after careful pretransplant assessment. The cumulative 6-month 
survival rate was 77%, a figure comparable to those for other 
indications. Recurrence to harmful drinking was extremely rare, 
likely due to the stringent selection criteria (first AH episode, 
support from family background, exclusion of psychiatric ill-
nesses, other substance abuse, consensus among OLT team 
members, absence of violence). This indication of liver trans-
plantation is increasingly accepted in many transplant centers 
including in the United State.139
After OLT, ALD patients require lifelong follow-up for pre-
vention and management of complications, just as all other 
OLT patients, too. As mentioned above, cardiovascular disease, 
chronic kidney disease, and cancer must be kept in mind. Calci-
neurin inhibitor-based immunosuppression (particularly cyclo-
sporine A) increase the risk of metabolic complications such as 
hypertension, diabetes, and dyslipidemia, which may contribute 
to the high incidence of cardiovascular disease and kidney dis-
ease in ALD patients. However, ALD is a good indication of OLT 
as demonstrated by data from the European Liver Transplant 
Registry, showing survival at 84%, 78%, 73%, and 58% after 1, 3, 
5, and 10 years, respectively, which is better than that with viral 
hepatitis and cryptogenic cirrhosis.16 
Patients transplanted due to ALD often present with multisys-
temic effects of long-term ethanol abuse.140 These comorbidities 
include malnutrition, muscle wasting due to alcoholic myopa-
thy, vitamin deficiencies, peripheral and central neural system 
abnormalities, and others. Therefore, the care of patients trans-
planted for ALD ideally calls for a multidisciplinary approach.
CONCLUSIONS
Although much insight has been gained in the epidemiology, 
pathophysiology and clinical diagnosis of ALD, the armoury of 
therapies is still disappointing. This lack of therapeutic options 
to treat AUD, ALD and related complications will only improve 
if more scientific, medical and societal attention is paid to this 
prevalent and deadly disease. A coalition among political, sci-
entific, and industry-based stakeholders is required to make a 
step forward. So far, these peers devoted the topic “ALD” only 
the role of a fringe group when drafting their health policies, re-
search efforts and conference programs. In essence, this attitude 
is a good example of a prepossession that made ALD an orphan 
disease in its own right. But ALD is a fully preventable disease, 
and more efforts should be made to use this fact as an advan-
tage.
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